NHC - National HealthCare Corporation
NYSE
->
Healthcare
->
Medical Care Facilities
Murfreesboro,
United States
Type: Equity
NHC price evolution
NHC
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $129.36 | $110.1 | $126.15 | $109.05 |
| Inventory | $7.84 | $6.63 | $6.76 | $7.39 |
| Total current assets | $445.73 | $447.87 | $417.59 | $406.24 |
| Long term investments | ||||
| Property, plant & equipment | $772.35 | $568.01 | $576.05 | $587.53 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1562.71 | $1339.7 | $1319.64 | $1310.8 |
| Current liabilities | ||||
| Accounts payable | $22.72 | $21.78 | $20.7 | $19.19 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $247.95 | $216.94 | $206.43 | $214.48 |
| Long term debt | $139.5 | |||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $579.24 | $393.88 | $394.89 | $402.04 |
| Shareholders' equity | ||||
| Retained earnings | $755.53 | $722.16 | $704.73 | $687.6 |
| Other shareholder equity | -$2.85 | -$5.91 | -$7.04 | -$6.6 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $109.05 | $100.29 | $96.58 | $90.6 |
| Inventory | $7.39 | $7.09 | $8.58 | $8.78 |
| Total current assets | $406.24 | $353.93 | $426.64 | $456.75 |
| Long term investments | ||||
| Property, plant & equipment | $587.53 | $627.05 | $677.11 | $699.37 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1310.8 | $1275.45 | $1403.4 | $1362.13 |
| Current liabilities | ||||
| Accounts payable | $19.19 | $16.96 | $22.49 | $21.11 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $214.48 | $197.89 | $263.2 | $281.23 |
| Long term debt | $0.86 | $5.84 | $10.54 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $402.04 | $401.17 | $500.39 | $566.96 |
| Shareholders' equity | ||||
| Retained earnings | $687.6 | $656.66 | $669.08 | $563.02 |
| Other shareholder equity | -$6.6 | -$9.53 | $1.6 | $5.06 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $340.2 | $300.66 | $297.18 | $300.91 |
| Cost of revenue | ||||
| Gross Profit | $126.8 | $120.58 | $114.04 | $114.35 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $104.01 | $98.06 | $98.36 | $94.18 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $15.34 | $9.49 | $9.46 | $8.7 |
| Interest expense | $35.25 | $14.08 | $19.01 | $16.49 |
| Net income | ||||
| Net income | $42.79 | $26.84 | $26.21 | $28.41 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1141.54 | $1085.74 | $1074.3 | $1028.22 |
| Cost of revenue | ||||
| Gross Profit | $429.2 | $399.57 | $455.64 | $434.13 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $371.74 | $370.84 | $374.09 | $336.91 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $23.45 | $7.25 | $10.95 | $10.43 |
| Interest expense | $31.28 | -$5.23 | $98.27 | $2.87 |
| Net income | ||||
| Net income | $66.8 | $22.45 | $138.59 | $41.87 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$225.05 | -$0.99 | -$2.42 | -$17.57 |
| Financing activities | ||||
| Dividends paid | -$27.55 | -$18.14 | -$9.05 | -$35.56 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $119.64 | -$19.68 | -$12.07 | -$42.55 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$10.89 | $39.64 | -$4.84 | $51.1 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$17.57 | -$5.98 | -$65.89 | -$63.88 |
| Financing activities | ||||
| Dividends paid | -$35.56 | -$34.6 | -$32.03 | -$31.92 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$42.55 | -$47.64 | -$35.26 | -$41.89 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $51.1 | -$44.88 | -$38.76 | $97.49 |
News
Fundamentals
| Market cap | $1.42B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 15.44M |
| Revenue | $1.24B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $124.25M |
| Revenue Q/Q | 25.61% |
| Revenue Y/Y | 12.16% |
| P/E ratio | 11.42 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.15 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $8.05 |
|---|---|
| ROA | 8.98% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.80 |
| Quick ratio | 1.77 |